These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15954909)

  • 1. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns.
    Rossing K; Mischak H; Parving HH; Christensen PK; Walden M; Hillmann M; Kaiser T
    Kidney Int; 2005 Jul; 68(1):193-205. PubMed ID: 15954909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic analysis for the assessment of diabetic renal damage in humans.
    Mischak H; Kaiser T; Walden M; Hillmann M; Wittke S; Herrmann A; Knueppel S; Haller H; Fliser D
    Clin Sci (Lond); 2004 Nov; 107(5):485-95. PubMed ID: 15281910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
    Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
    Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
    Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
    Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
    Rossing K; Jacobsen P; Pietraszek L; Parving HH
    Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S;
    Hypertens Res; 2008 Apr; 31(4):657-64. PubMed ID: 18633177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
    Rossing K; Christensen PK; Hansen BV; Carstensen B; Parving HH
    Diabetes Care; 2003 Jan; 26(1):150-5. PubMed ID: 12502672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
    Andersen S; Mischak H; Zürbig P; Parving HH; Rossing P
    BMC Nephrol; 2010 Nov; 11():29. PubMed ID: 21040538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
    J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study.
    Saha SA; LaSalle BK; Clifton GD; Short RA; Tuttle KR
    Am J Ther; 2010; 17(6):553-8. PubMed ID: 19829095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
    Krimholtz MJ; Karalliedde J; Thomas S; Bilous R; Viberti G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S42-7. PubMed ID: 15938033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker.
    Wang G; Lai FM; Lai KB; Chow KM; Kwan BC; Li PK; Szeto CC
    Eur J Endocrinol; 2008 Mar; 158(3):317-22. PubMed ID: 18299464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
    Yoshida S; Hashimoto T; Kihara M; Imai N; Yasuzaki H; Nomura K; Kiuchi Y; Tamura K; Ishigami T; Hirawa N; Toya Y; Kitamura H; Umemura S
    Nephron Exp Nephrol; 2009; 111(1):e20-30. PubMed ID: 19052474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.